Download video

GLP-1 receptor agonists in patients with CKD not on dialysis; beyond cardiorenal protection

794 views

ERA - European Renal Association

1 year ago

GLP-1 receptor agonists in patients with CKD not on dialysis; beyond cardiorenal protection

GLP-1 receptor agonists in patients with CKD not on dialysis; beyond cardiorenal protection

GLP-1 receptor agonists in patients with CKD not on dialysis; beyond cardiorenal protection
45:30
GLP-1 receptor agonists in patients with CKD not on dialysis; beyond cardiorenal protection
by ERA - European Renal Association
Ian de Boer, MD, MS - GLP-1 Receptor Agonists for Patient with Kidney Disease
31:29
Ian de Boer, MD, MS - GLP-1 Receptor Agonists for Patient with Kidney Disease
by University of Washington Division of Nephrology
SGLT2i, GLIP-1A and MRA in Cardiorenal Protection | Monique Cho
1:04:03
SGLT2i, GLIP-1A and MRA in Cardiorenal Protection | Monique Cho
by Ogden Surgical-Medical Society
Optimizing Cardiovascular, Renal Prognosis in Diabetes with GLP-1, SGLT2 Combination
4:14
Optimizing Cardiovascular, Renal Prognosis in Diabetes with GLP-1, SGLT2 Combination
by HCPLive
Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists
6:11
Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists
by Harvard Medical School Continuing Education
Chronic Kidney Disease and GLP-1 RAs
28:17
Chronic Kidney Disease and GLP-1 RAs
by American Heart Association
Scoring Comprehensive T2DM Management Goals: Multifaceted Effects of GLP-1 Receptor Agonists
1:04:19
Scoring Comprehensive T2DM Management Goals: Multifaceted Effects of GLP-1 Receptor Agonists
by PeerView CME
Using GLP-1 RAs to Individualize Therapy in T2DM
1:19:59
Using GLP-1 RAs to Individualize Therapy in T2DM
by PeerView CME
GLP-1 in kidney transplantation-is it feasible?
1:02:39
GLP-1 in kidney transplantation-is it feasible?
by ERA - European Renal Association
KDIGO Individual Optimization of Management of CKD Patients with Diabetes and CVD Comorbidities
1:00:57
KDIGO Individual Optimization of Management of CKD Patients with Diabetes and CVD Comorbidities
by KDIGO
New Glucose-Lowering Drugs and Kidney Protection in CKD
1:05:08
New Glucose-Lowering Drugs and Kidney Protection in CKD
by GlomCon Foundation
GLP-1 Receptor Agonists and Diabetic KidneyDisease: A Call of Attention to Nephrologists
1:04
GLP-1 Receptor Agonists and Diabetic KidneyDisease: A Call of Attention to Nephrologists
by Sociedad Valenciana de Nefrología
EASD 2023 - Benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control
24:20
EASD 2023 - Benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control
by European Association for the Study of Diabetes
Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists
7:43
Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists
by Harvard Medical School Continuing Education
GMO Dialogues | Impacts of GLP-1 Receptor Agonists and SGLT-2 Inhibitor on CKD with Dr Frank Maddux
38:25
GMO Dialogues | Impacts of GLP-1 Receptor Agonists and SGLT-2 Inhibitor on CKD with Dr Frank Maddux
by Fresenius Medical Care
Prof Melanie Davies - 'Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes?'
26:43
Prof Melanie Davies - 'Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes?'
by At the Limits - Leading Medical Education
Grand Rounds – DPP-4 Inhibitors And GLP-1 Agonists: The Perfect Pairing, Or Better Off Alone?
52:47
Grand Rounds – DPP-4 Inhibitors And GLP-1 Agonists: The Perfect Pairing, Or Better Off Alone?
by Family \& Community Medicine Grand Rounds
Facebook Live: What do I Need to Know about Medications?
35:59
Facebook Live: What do I Need to Know about Medications?
by National Kidney Foundation
Zooming in on Cardiovascular Risk Control With Glucagon-Like Peptide-1 Receptor Agonists in Diabetes
16:41
Zooming in on Cardiovascular Risk Control With Glucagon-Like Peptide-1 Receptor Agonists in Diabetes
by Medscape
Individualizing Treatment With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM
53:02
Individualizing Treatment With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM
by PeerView CME